Pharmaceutical and biopharmaceutical companies are focusing more on their respective core strengths to manage the rising price pressure. Thus, the demand for contract manufacturing is increasing. However, vaccine manufacturing is a complex venture, in which safety, effectivity, and consistency are the most challenging part for the manufacturers. It offer many services that include production process, construction and operation of manufacturing product, cell line development, fermentation, process optimization, and analytical characterization, which fuels growth of the global vaccine contract manufacturing market.
Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1083
Increase in research activities for new vaccines and availability of funds for the same could be the key growth factor of vaccine contract manufacturing market
Soligenix Inc. received a fund of around US$ 2.5 million for the contract of bioterror vaccine from National Institute of Allergy and Infectious Diseases (NIAID) in August 2017. The fund is granted for good manufacturing practices (GMP) of RiVax bulk drug substances and finished drug manufacturing to conduct future preclinical, clinical, and efficacy studies. Soligenix is aiming to develop advanced Soligenix’s thermostabilization technology (ThermoVax) in combination with ricin toxin vaccine candidate – RiVax. The studies are conducting to prevent the effects of ricin exposure.
Colorado State University’s (CSU) vaccine manufacturing facility, BioMARK, is developing a vaccine against a mosquito borne viral pathogen, which causes Venezuelan equine encephalitis (VEE). The U.S. Department of Defense (DoD) has funded around US$ 3 million to BioMARK for the development of this vaccine The purpose of this vaccine is to protect U.S. soldiers from fatal mosquito-borne pathogen. However, CSU is a subcontractor in vaccine project of Battelle and DoD’s Medical Countermeasure Systems Joint Vaccine Acquisition Program. CSU is determined to develop vaccine against aerosolized viruses to protect U.S. soldiers.
Emergent BioSolutions agreed to sign a contract with the Centers for Disease Control and Prevention (CDC) for the manufacturing of BioThrax anthrax vaccine in 2016. According to the contract, Emergent will supply over 29 million doses of BioThrax anthrax vaccine in five years period of worth around US$ 911 million. Moreover, Biomedical Advanced Research and Development Authority planned to order more Bio Thrax worth US$ 100 million. This would further augment growth of the global vaccine contract manufacturing market in the near future.
Minneapolis Medical Research Foundation (MMRF) – subsidiary of the Hennepin Healthcare System, Inc. – decided to enter a contract with Goodwin Biotechnology Inc., in March 2017, to develop and manufacture two vaccines to treat opioid. The research is funded by National Institute on Drug Abuse for next three years (2017 to 2019) grant to MMRF.
Bavarian Nordic A/S has received a source contract from Biomedical Advanced Research and Development Authority (BARDA) for the manufacturing and storage of freeze-dried IMVAMUNE smallpox vaccine in September 2017. According to the contract, Bavarian will provide services for clinical development, regulatory commitments, establishment, and validation of fill-finish activities for manufacturing of the product.
In September 2017, Thomas Jefferson University received contract of around US$ 2.6 million from National Institute of Allergy and Infectious Diseases (NIAID) to prepare and test vaccine formulation against Ebola, Sudan, Marburg, and Lassa fever viruses. This would be the first tetravalent vaccine to enhance protection against four hemorrhagic fever viruses, which has high mortality rate by damaging blood vessels and cause internal bleeding.
Increasing prevalence of various viral and bacterial infections is expected to fuel growth of the market
According to World Health Organization (WHO), in 2016, around three to five million cases were recorded with severe illness and around 250,000 to 500,000 deaths were estimated due to influenza worldwide.
In 1952, Centers for Disease Control and Prevention (CDC) collaborated with the World Health Organization’s (WHO), under the program – Global Influenza Surveillance and Response System (GISRS). The GISRS network consist of around 142 National Influenza Centers (NICS) worldwide, which are conducting influenza surveillance and viral trends in 112 countries. The study helps in research and analysis of influenza pattern and may contribute to develop candidate vaccines. This in turn, fuels growth of the vaccine contract manufacturing market.
The key players operating in the global vaccine contract manufacturing market include Soligenix Inc., Bavarian Nordic A/S, Goodwin Biotechnology Inc., BioMARK, Emergent BioSolutions, Catalent Biologics, FUJIFILM Diosynth Biotechnologies, Thomas Jefferson University, and Minneapolis Medical Research Foundation (MMRF).
Request for complete TOC of this report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1083
Global Vaccine Contract Manufacturing Market Taxonomy:
On the basis of service type, vaccine type, and product type, the global vaccine contract manufacturing market is segmented into,
By Service Type: Fill-Finish, Bulk product,.
By Vaccine Type: Subunit Vaccines, Live Attenuated Vaccines, Conjugate Vaccines, Inactivated Vaccines, Recombinant Vector Vaccines, Toxoid Vaccines, Synthetic Vaccines,.
By Product Type: Single Vaccine, Ebola Virus, Influenza Virus, Smallpox, Chickenpox, Tetanus, Polio, Tuberculosis, Others, Combination Vaccine,.